Clinical Trials

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

Neurizon Therapeutics completes enrollment for its NUZ-001 ALS trial at record speed, accelerating the timeline for potential new treatment data to 2027.

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

A Dutch med-tech firm's sutureless device, validated in a key trial, could make bypass surgery faster, safer, and more accessible via robotics.

With its MASH drug Rezdiffra a certified blockbuster, Madrigal's upcoming Q2 report will reveal if its meteoric rise can be sustained against new rivals.

With its lead gene therapy nearing pivotal data, enGene installs a new chairman with a track record of commercial success, signaling a critical shift from R&D to market readiness.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.

Beyond GLP-1, Boehringer Ingelheim’s new drug targets the brain's hunger signals, a calculated move in the high-stakes race for obesity treatment.

As Celldex nears pivotal data for its lead drug, the planned retirement of its long-serving CFO marks a strategic pivot toward becoming a commercial powerhouse.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.

As federal mandates push to end decades of stagnation, one company's 'truly real-time' platform offers a foundational fix for drug development.

A startling case study suggests lifelong heat exposure may build resilience against Alzheimer's. Now, medical researchers are turning to infrared saunas.

A new bispecific antibody from Kelun-Biotech and Harbour BioMed just got a green light in China, promising quarterly doses for asthma. Is this the innovation that finally unseats the market giants?

RNAi pioneer Alnylam unveils promising data for its gene-silencing drugs, targeting Alzheimer's and CAA at their genetic source and offering new hope.

Genentech's Gazyva gains FDA Priority Review for a rare kidney disease with no approved treatments, signaling a potential paradigm shift for patients.

Seattle's Sound Pharma completes key Phase 3 enrollment for SPI-1005, putting the first-ever approved drug for debilitating Meniere's disease on the horizon.

Ironwood Pharmaceuticals appoints a veteran CMO and launches a key Phase 3 trial, signaling a strategic pivot beyond its blockbuster to conquer rare diseases.

A U.S.-China partnership is testing a drug that could replace cataract surgery. The ZOC2017217 eye drop aims to reverse vision loss for millions.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.